These findings imply an intricate interplay between BRCA1 and BRCA2 PVs in our CRC patient cohort, without significantly amplifying cancer risk or introducing distinct phenotypic characteristics beyond what would be expected from an individual BRCA variant. The gene discussed is BRCA2; the disease is cancer.